The latest news for pharma industry insiders.
AI in Clinical Trials: The Future of Drug Discovery
Despite the significance offered by AI to pharmaceutical companies, there are several challenges that must be overcome for successful integration of tech-based tools.
The 2024 Asembia Meeting is Underway
GLP-1s, artificial intelligence and the Inflation Reduction Act are among the topics featured in the education sessions of the specialty pharmacy meeting in Las Vegas. The keynote speaker is William McRaven, a retired four-star admiral and former chancellor of the University of Texas system.
AI Start-Ups Face a Rough Financial Reality Check
The table stakes for small companies to compete with the likes of Microsoft and Google are in the billions of dollars. And even that may not be enough.
Talkspace announced the launch of its Behavioral Health Consortium, a curated network of specialty providers featuring Charlie Health, Ria Health, Bicycle Health, and more. This consortium enables Talkspace clinicians to refer insured members to like-minded, in-network, clinically-vetted specialty care providers who provide a higher level of care for higher acuity needs such as treatment for alcoholism, substance use, and eating disorders.
Many thanks to Miranda Schmalfuhs at Pharmaceutical Executive for being a gracious host with insightful questions on Dotmatics Luma and Luma Lab Connect! Have a listen - you'll hear discussion about key Lab Connect benefits, the unique value that the Luma ecosystem + integrated scientific tools (such as GraphPad Prism, Geneious Prime & Biologics, SnapGene, Protein Metrics, LLC, Omiq) bring to the table, and implications for the industry.
Scientific instruments and wet lab research are crucial, but they're only one chapter in the larger story around AI-assisted simulation. Luma is at the center of that story, with hundreds of research scientists processing 10s of terabytes of FAIR data each day across thousands of instruments.
https://lnkd.in/d8xVKaUC
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs